AroCell AB: announces that a distribution agreement has been signed with Pathway Diagnostics Ltd, for distribution of the AroCell TK 210 ELISA test in United Kingdom and Ireland.

Friday, 13 October 2017  (6 days ago)
"We very much look forward to this new collaboration with the England based Pathway Diagnostics for the distribution of our TK 210 ELISA test", states Jan Stålemark, AroCell CEO. "Pathway Diagnostics Ltd is a leading supplier of specialist clinical and research diagnostics in the UK and was established in 1998 to provide high quality in-vitro diagnostic products and instrumentation to clinical, research and industrial laboratories mainly in the UK and Ireland. Pathway Diagnostics are highly focused on the needs of their customers and in providing the highest quality products and service and therefore we consider them as a perfect match for our TK 210 ELISA test."

The TK 210 ELISA test will be commercially available immediately through Pathway Diagnostics in the UK and Irish market.

* For additional information:
* Jan Stålemark, CEO
AroCell AB (publ)
Tel: +46(0)706926206
info@arocell.com
www.arocell.com

This information is information that AroCell is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through Jan Stålemark, at 08:50 CET on 13 October 2017.

* About AroCell
* AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure (Thymidine Kinase 1 (TK1) protein levels in a blood sample. The TK 210 ELISA test provide valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of the tumor disease during  monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North and has about 2,500 shareholders. For more information, please see  www.arocell.com . Redeye AB is AroCell's Certified Adviser.

Press Release Distribution UK20171011_final
--------------------This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: AroCell AB via GlobeNewswire

HUG#2141700

Recent related news

CAMBRIDGE, Mass.--(BUSINESS WIRE)--GenePeeks announced an exclusive distribution agreement with CORE Diagnostics of India to deliver preconception screening...
2 days ago • Business Wire
LONDON, UNITED KINGDOM--(Marketwired - Oct 17, 2017) - Huawei announces they have successfully completed an LTE-Advanced Pro technology test at Wembley Stadium...
2 days ago • Marketwired
A prospective, multicenter, cross-sectional study of adults and children with URIs was performed to evaluate the diagnostic accuracy of the FebriDx test to...
1 week ago • PRWeb
OXFORD, England--(BUSINESS WIRE)--Blue Earth Diagnostics, a molecular imaging diagnostics company, and Seibersdorf Laboratories, a leading developer and...
1 week ago • Business Wire
Ireland will play Pakistan on home soil in May in their first ever Test match. Ireland were given Test status in June and have secured their first fixture...
1 week ago • MailOnline

You might like